Do you recommend on-demand versus fixed-schedule dosing for rituximab maintenance in ANCA vasculitis?
If you use both, how do you decide which to use for a particular patient?
Answer from: at Community Practice
This is a fairly hot question in the field, and one that reflects the success we have had with advancing therapy for ANCA-associated vasculitis; it’s nice to have choices!
Although there are data for both approaches, there are more data (larger numbers, etc.), in my opinion, for fixed-dosing....
Sign in or Register to read more
Answer from: at Academic Institution
This is a great question and one that does not have a definitive right answer. However, there is significant data in this area:- Longer maintenance of remission (with RTX or other agents) reduces flares (REMAIN, Terrier et al., PMID 29724729).- Patients with absent B-cells flare at much lower rates ...